U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT06855147) titled 'Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects' on Feb. 25.
Brief Summary: This study was a single-center, single-dose, open-label study in healthy male subjects to investigate the absorption, metabolism and excretion of HRS9531 after a single subcutaneous injection of [14C]HRS9531.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes Mellitus
Weight Loss
Intervention:
DRUG: [14C]HRS9531
A single dose of [14C]HRS9531 injected subcutaneously.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permis...